Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess objective tumor response in the single agent treatment
of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or
gastroesophageal junction adenocarcinoma